Jan 15 (Reuters) - CSPC Pharmaceutical Group Ltd
:
* BISPECIFIC FUSION PROTEIN DRUG JMT106 OBTAINS CLINICAL TRIAL APPROVAL IN U.S. BY U.S. FDA
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Jan 15 (Reuters) - CSPC Pharmaceutical Group Ltd
:
* BISPECIFIC FUSION PROTEIN DRUG JMT106 OBTAINS CLINICAL TRIAL APPROVAL IN U.S. BY U.S. FDA
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Comments